precisionmedicineonline3m
Neurogene Halts Testing High-Dose Rett Syndrome Gene Therapy After Adverse Event
Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.
precisionmedicineonline5m
Cure51 Partners With Cambridge University Hospitals, Others to Expand Cancer Survival Study to UK
Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.
precisionmedicineonline2d
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
precisionmedicineonline3d
After Success in Treating Cancer, CAR T Cells Break Into Autoimmune, HIV, and More
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
precisionmedicineonline4d
Genetic Testing Challenges in Precision Medicine: Li-Fraumeni Diagnosis Missed in Young Patient
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
precisionmedicineonline4d
McKesson Bets on Cell, Gene Therapy Products as it Corrals Services in New Business Unit
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...
precisionmedicineonline2d
Giostar Gearing up for Phase II Trial of Type 2 Diabetes Stem Cell Therapy in US
The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.
precisionmedicineonline2d
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
precisionmedicineonline2d
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
precisionmedicineonline2d
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.